Cover Image

2‐Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size

Abstract IDH1/2 mutations occur at high frequency in diffusely infiltrating gliomas of the WHO grades II and III and were identified as a strong prognostic marker in all WHO grades of gliomas. Mutated IDH1 or IDH2 protein leads to the generation of excessive amounts of the metabolite 2?hydroxyglutar...

Full description

Saved in:
Bibliographic Details
Main Authors: Capper, David (Author) , Simon, Matthias (Author) , Langhans, Claus-Dieter (Author) , Okun, Jürgen G. (Author) , Tonn, Jörg-Christian (Author) , Weller, Michael (Author) , Deimling, Andreas von (Author) , Hartmann, Christian (Author)
Format: Article (Journal)
Language:English
Published: 1 August 2012
In: International journal of cancer
Year: 2012, Volume: 131, Issue: 3, Pages: 766-768
ISSN:1097-0215
DOI:10.1002/ijc.26425
Online Access:Verlag, Volltext: http://dx.doi.org/10.1002/ijc.26425
Verlag, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.26425
Get full text
Author Notes:Capper David, Simon Matthias, Langhans Claus‐Dieter, Okun Jürgen G., Tonn Jörg C., Weller Michael, Deimling Andreas von, Hartmann Christian
Description
Summary:Abstract IDH1/2 mutations occur at high frequency in diffusely infiltrating gliomas of the WHO grades II and III and were identified as a strong prognostic marker in all WHO grades of gliomas. Mutated IDH1 or IDH2 protein leads to the generation of excessive amounts of the metabolite 2?hydroxyglutarate (2HG) in tumor cells. Here, we evaluated whether 2HG levels in preoperative serum samples from patients with gliomas correlate with the IDH1/2 mutation status and whether there is an association between 2HG levels and glioma size. In contrast to the strong accumulation of 2HG in the serum of patients with IDH1/2 mutated acute myeloid leukaemia, no accumulation was observed in this series of IDH1/2 mutated gliomas. Furthermore, we found no association between glioma size measured by magnetic resonance imaging and 2HG levels. We conclude that 2HG levels in preoperative sera from patients with diffusely infiltrating gliomas of the WHO grades II and III cannot be used as a marker to differentiate between tumors with versus without IDH1/2 mutation. Furthermore, the observation that there is no correlation between 2HG levels and tumor volume may indicate that 2HG cannot be utilized as marker to monitor tumor growth in gliomas.
Item Description:Gesehen am 18.04.2018
Physical Description:Online Resource
ISSN:1097-0215
DOI:10.1002/ijc.26425

Similar Items